Meeker David P 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Meeker David P
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2025-02-16+21,250→ 211,177 total - Sale
Common Stock
2025-02-19$57.22/sh−9,896$566,249→ 201,281 total - Award
Restricted Stock Units
2025-02-14+133,350→ 133,350 total→ Common Stock (133,350 underlying) - Award
Stock Options (Right to Buy)
2025-02-14+200,000→ 200,000 totalExercise: $56.69Exp: 2035-02-13→ Common Stock (200,000 underlying) - Exercise/Conversion
Restricted Stock Units
2025-02-16−21,250→ 63,750 total→ Common Stock (21,250 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- [F3]The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.
- [F4]The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- [F5]The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.